OBJECTIVE： To evaluate the economics of hemocoagulase agkistrodon used in neurosurgery operation. METHODS： Based on the public information and literature， the study used blood loss and the incidence of postoperative hematoma as outcome index， and the patient cohort was simulated by Monte Carlo. At last， the research used cost effectiveness method for economic evaluation combining with cost data. RESULTS： The incidence of postoperative hematoma in hemocoagulase agkistrodon group decreased by 1.24％， and the incremental cost was 32 560 yuan （＜GDP per capita）. The sensitivity analysis supported the stability of the results. CONCLUSIONS： It is worth to spend the incremental cost which was induced by that hemocoagulase agkistrodon reduce the incidence of postoperative hematoma in neurosurgery surgery and it owns cost effectiveness.